Novo Nordisk reported Q1 net sales of $15.2 billion, surpassing estimates due to high demand for its oral weight-loss pill Wegovy and strong international sales. Operating profit nearly doubled to $9.4 billion, with gross margin expanding to 85.9%. The company raised its 2026 guidance, expecting a smaller decline in adjusted sales and operating profit growth. Wegovy's oral version generated $354 million in sales with over 1 million patients using it since January. Novo Nordisk also advanced its diabetes and sickle cell disease treatments with recent FDA approvals and successful trials.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
